Indegene Q3 FY26: Revenue up 31% YoY to Rs 942 cr, PAT flat at Rs 103 cr

Revenue growth above 20%Results View source PDF Explain this filing

INDGN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹469.00

prior close

₹464.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.9%+2.3% vs market

Healthcare Services peers, median of 56sector · industry level+1.0%+2.2% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Smallcap 250 and 2.2 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.6

15m

+1.8

30m

+2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1+0.9+2.3+1.0+2.2

Next day

+4.5-0.8+5.3+1.4+3.0

+6.8+2.1+4.7+2.8+4.1

+2.4+2.9-0.5+2.9-0.5

+2.1+1.8+0.2+3.0-0.9

+3.6+1.5+2.1+4.2-0.6

+4.1+4.6-0.5+5.5-1.4

15d

+3.2+2.1+1.1+2.9+0.3

+2.6-0.3+2.9-0.9+3.4

-7.4-8.6+1.2-8.2+0.8

+6.8+7.0-0.2+3.9+2.9

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 56Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 consolidated revenue rose 30.8% YoY to Rs 9,421 mn from Rs 7,204 mn; PAT at Rs 1,029 mn vs Rs 1,097 mn (slight decline). 9M FY26 revenue up 20.3% YoY at Rs 25,071 mn, PAT up 11.2% at Rs 3,214 mn. EPS Rs 4.29 basic for the quarter. Three acquisitions during the quarter: BioPharm (USD 104 mn closed Oct 1), Warn and Co (GBP 3.91 mn closed Oct 16), and Cake Group SPA signed (up to EUR 8.5 mn). US class action TCPA lawsuit ongoing, no provision made. Deloitte gave unmodified review opinion.

Likely market impact

Strong revenue growth driven by acquisitions; Q3 PAT slightly lower YoY on higher costs. Watch BioPharm integration and US lawsuit outcome.